Literature DB >> 8239269

Receptor-coupled amyloid precursor protein processing.

R M Nitsch1, B E Slack, S A Farber, P R Borghesani, J G Schulz, C Kim, C C Felder, J H Growdon, R J Wurtman.   

Abstract

The family of beta-amyloid protein precursors (APP) can be processed via several alternative proteolytic pathways. Some generate potentially amyloidogenic APP derivatives, whereas others preclude the formation of such fragments. The cellular mechanisms regulating the relative activities of these pathways are thus important in determining the factors contributing to the formation of amyloidogenic APP derivatives. In order to investigate whether cell-surface receptor activity can regulate APP processing, HEK 293 cell lines stably expressing human muscarinic acetylcholine receptors (mAChR; subtypes m1, m2, m3, m4) were stimulated with the muscarinic agonist carbachol, and the release of APP derivatives was measured. Carbachol increased the release of large amino-terminal APP-fragments 4- to 6-fold in cell lines expressing the m1 or m3 receptors but not in those expressing m2 or m4 subtypes. This increase was blocked by various protein kinase inhibitors and mimicked by phorbol esters, indicating that it is mediated by protein kinase activation, presumably by protein kinase C (PKC). To determine whether additional cell-surface receptor types linked to this signal transduction pathway could also regulate APP processing, we stimulated differentiated PC-12 cells with bradykinin and found that this neuropeptide also increased the secretion of amino-terminal APP derivatives. We next investigated the possibility that neuronal depolarization might affect APP processing in mammalian brain. Electrically stimulated rat hippocampal slices released two times more amino-terminal APP derivatives than unstimulated control slices. This release increased with increasing stimulation frequencies in the physiological firing range of hippocampal pyramidal cells, and was blocked by tetrodotoxin. These results suggest that, in brain, APP processing is regulated by neuronal activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239269     DOI: 10.1111/j.1749-6632.1993.tb23039.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Rapid stimulation of amyloid precursor protein release by epidermal growth factor: role of protein kinase C.

Authors:  B E Slack; J Breu; L Muchnicki; R J Wurtman
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

2.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

Review 3.  P2Y2 nucleotide receptor-mediated responses in brain cells.

Authors:  Troy S Peterson; Jean M Camden; Yanfang Wang; Cheikh I Seye; W G Wood; Grace Y Sun; Laurie Erb; Michael J Petris; Gary A Weisman
Journal:  Mol Neurobiol       Date:  2010-04-13       Impact factor: 5.590

4.  Cysteine 27 variant of the delta-opioid receptor affects amyloid precursor protein processing through altered endocytic trafficking.

Authors:  Timo Sarajärvi; Jussi T Tuusa; Annakaisa Haapasalo; Jarkko J Lackman; Raija Sormunen; Seppo Helisalmi; Johannes T Roehr; Antonio R Parrado; Petra Mäkinen; Lars Bertram; Hilkka Soininen; Rudolph E Tanzi; Ulla E Petäjä-Repo; Mikko Hiltunen
Journal:  Mol Cell Biol       Date:  2011-04-04       Impact factor: 4.272

Review 5.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 6.  Protein phosphorylation and APP metabolism.

Authors:  Edgar F da Cruz e Silva; Odete A B da Cruz e Silva
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

Review 7.  New prospects and strategies for drug target discovery in neurodegenerative disorders.

Authors:  Brian S Hilbush; John H Morrison; Warren G Young; J Gregor Sutcliffe; Floyd E Bloom
Journal:  NeuroRx       Date:  2005-10

Review 8.  Signal transduction therapeutics: relevance for Alzheimer's disease.

Authors:  Odete A B da Cruz e Silva; Margarida Fardilha; Ana Gabriela Henriques; Sandra Rebelo; Sandra Vieira; Edgar F da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

10.  A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of β-amyloid production.

Authors:  Vinod Udayar; Virginie Buggia-Prévot; Rita L Guerreiro; Gabriele Siegel; Naresh Rambabu; Amanda L Soohoo; Moorthi Ponnusamy; Barbara Siegenthaler; Jitin Bali; Mikael Simons; Jonas Ries; Manojkumar A Puthenveedu; John Hardy; Gopal Thinakaran; Lawrence Rajendran
Journal:  Cell Rep       Date:  2013-12-26       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.